Sagent launches new heart injection

SCHAUMBURG - Sagent Pharmaceuticals Inc., a privately held specialty pharmaceutical company, announced it has launched amiodarone HCl injection, USP, a class III antiarrhythmic indicated for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia - a potentially life-threatening irregular heart beat. According to IMS data, 2007 sales of injectable amiodarone in the United States were approximately $8 million.